Fallopian tube endometrioid adenocarcinoma
diseaseOn this page
Also known as endometrioid adenocarcinoma of fallopian tubeendometrioid adenocarcinoma of the fallopian tubeendometrioid carcinoma of fallopian tubeendometrioid carcinoma of the fallopian tubefallopian tube endometrioid carcinoma
Summary
Fallopian tube endometrioid adenocarcinoma (MONDO:0003666) is a disease and 35 clinical trials. Top therapeutic interventions include paclitaxel, topotecan, and olaparib. A subtype of fallopian tube adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 35
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | fallopian tube endometrioid adenocarcinoma |
| Mondo ID | MONDO:0003666 |
| DOID | DOID:5831 |
| NCIT | C6279 |
| UMLS | C1333592 |
| MedGen | 232185 |
| GARD | 0023612 |
| Anatomy (UBERON) | UBERON:0003889 |
| Is cancer (heuristic) | no |
Also known as: endometrioid adenocarcinoma of fallopian tube · endometrioid adenocarcinoma of the fallopian tube · endometrioid carcinoma of fallopian tube · endometrioid carcinoma of the fallopian tube · fallopian tube endometrioid adenocarcinoma · fallopian tube endometrioid carcinoma
Disease family
This is a subtype of fallopian tube adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › fallopian tube adenocarcinoma › fallopian tube endometrioid adenocarcinoma
Related subtypes (4): fallopian tube mucinous adenocarcinoma, fallopian tube clear cell adenocarcinoma, fallopian tube papillary adenocarcinoma, fallopian tube serous adenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 35.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 13 |
| PHASE3 | 7 |
| PHASE1 | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00565851 | PHASE3 | ACTIVE_NOT_RECRUITING | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT01167712 | PHASE3 | ACTIVE_NOT_RECRUITING | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT02502266 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer |
| NCT02839707 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT06580314 | PHASE3 | RECRUITING | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer |
| NCT00108745 | PHASE3 | UNKNOWN | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00262847 | PHASE3 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00719303 | PHASE3 | UNKNOWN | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00951496 | PHASE3 | COMPLETED | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT02068794 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| NCT02345265 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer |
| NCT03587311 | PHASE2 | ACTIVE_NOT_RECRUITING | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT04034927 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer |
| NCT04739800 | PHASE2 | ACTIVE_NOT_RECRUITING | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
| NCT04919629 | PHASE2 | RECRUITING | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion |
| NCT05231122 | PHASE2 | RECRUITING | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer |
| NCT05920798 | PHASE1/PHASE2 | RECRUITING | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT06639074 | PHASE2 | RECRUITING | Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial |
| NCT00888615 | PHASE2 | COMPLETED | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT01097746 | PHASE2 | COMPLETED | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
| NCT02364713 | PHASE2 | TERMINATED | MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
| NCT02713386 | PHASE1/PHASE2 | COMPLETED | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02853318 | PHASE2 | COMPLETED | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT02923739 | PHASE2 | TERMINATED | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT05295589 | PHASE2 | WITHDRAWN | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy |
| NCT04092270 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer |
| NCT05276973 | PHASE1 | ACTIVE_NOT_RECRUITING | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer |
| NCT00989651 | PHASE1 | COMPLETED | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT01074411 | PHASE1 | COMPLETED | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT03924245 | PHASE1 | TERMINATED | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers |
| NCT05415709 | EARLY_PHASE1 | RECRUITING | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer |
| NCT01504126 | EARLY_PHASE1 | COMPLETED | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00899093 | Not specified | TERMINATED | YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy |
| NCT03641287 | Not specified | TERMINATED | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PACLITAXEL | 4 | 17 |
| TOPOTECAN | 4 | 4 |
| OLAPARIB | 4 | 3 |
| ATEZOLIZUMAB | 4 | 1 |
| BEVACIZUMAB | 4 | 1 |
| COPANLISIB HYDROCHLORIDE | 4 | 1 |
| DIPHTHERIA TOXOID | 4 | 1 |
| GEMCITABINE HYDROCHLORIDE | 4 | 1 |
| PEGCETACOPLAN | 4 | 1 |
| RUXOLITINIB | 4 | 1 |
| TETANUS TOXOID | 4 | 1 |
| CEDIRANIB | 3 | 5 |
| VELIPARIB | 3 | 2 |
| ELESCLOMOL | 3 | 1 |
| EMACTUZUMAB | 3 | 1 |
| ENTINOSTAT | 3 | 1 |
| IPATASERTIB | 3 | 1 |
| PACLITAXEL POLIGLUMEX | 3 | 1 |
| ANETUMAB RAVTANSINE | 2 | 1 |
| NEDISERTIB | 1 | 1 |
| CHEMBL5412235 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |